Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
2
TTOO Quote, Financials, Valuation and Earnings
Last price:
$0.0100
Seasonality move
:
-12.84%
Day range:
$0.0020 - $0.0100
52-week range:
$0.0001 - $0.4500
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.01x
P/B ratio:
--
Volume:
32.8K
Avg. volume:
97.6K
1-year change:
-98.81%
Market cap:
$140.2K
Revenue:
$7.2M
EPS (TTM):
-$6.42
Analysts' Opinion
-
Consensus RatingT2 Biosystems, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.0000, T2 Biosystems, Inc. has an estimated upside of 99900% from its current price of $0.0050.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.0000 representing 100% downside risk from its current price of $0.0050.
Fair Value
-
According to the consensus of 1 analyst, T2 Biosystems, Inc. has 99900% upside to fair value with a price target of $3.0000 per share.
TTOO vs. S&P 500
-
Over the past 5 trading days, T2 Biosystems, Inc. has overperformed the S&P 500 by 1587.22% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
T2 Biosystems, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
T2 Biosystems, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter T2 Biosystems, Inc. reported revenues of $2M.
Earnings Growth
-
T2 Biosystems, Inc. has grown year-over-year earnings for 9 quarters straight. In the most recent quarter T2 Biosystems, Inc. reported earnings per share of -$0.57.
Enterprise value:
17M
EV / Invested capital:
--
Price / LTM sales:
0.01x
EV / EBIT:
--
EV / Revenue:
2.21x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.46x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$5.9M
Return On Assets:
-150.57%
Net Income Margin (TTM):
-559.52%
Return On Equity:
--
Return On Invested Capital:
-478.19%
Operating Margin:
-511.89%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $23.8M | $11M | $7.7M | $1.5M | $2M | |
| Gross Profit | $1.1M | -$5.8M | -$6M | -$2.6M | -$2.1M | |
| Operating Income | -$56M | -$46.7M | -$41.7M | -$11.1M | -$10.2M | |
| EBITDA | -$53.7M | -$44.7M | -$41.4M | -$10.8M | -$10.1M | |
| Diluted EPS | -$1,655.65 | -$283.67 | -$6.41 | -$3.45 | -$0.57 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $51.4M | $54.4M | $28.9M | $32.9M | $9.8M | |
| Total Assets | $77.6M | $70M | $44M | $43.3M | $18.1M | |
| Current Liabilities | $10.4M | $11.4M | $10.9M | $55.5M | $24.4M | |
| Total Liabilities | $60.1M | $72.5M | $75.3M | $62.5M | $29.8M | |
| Total Equity | $17.6M | -$2.5M | -$31.3M | -$19.2M | -$11.7M | |
| Total Debt | $45.1M | $56.8M | $57.8M | $47.9M | $17.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$50.1M | -$49.1M | -$36.6M | -$13.5M | -$6.3M | |
| Cash From Investing | $19.5M | -$202K | -$26K | -$13K | -- | |
| Cash From Financing | $28.5M | $52.7M | $14.4M | $21.7M | $4.1M | |
| Free Cash Flow | -$50.6M | -$49.3M | -$36.6M | -$13.5M | -$6.3M | |
TTOO
Sector
Market Cap
$140.2K
$28.1M
Price % of 52-Week High
1.11%
50%
Dividend Yield
0%
0%
Shareholder Yield
-17.93%
-1.54%
1-Year Price Total Return
-98.81%
-17.67%
Beta (5-Year)
0.743
0.503
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0107
200-day SMA
Sell
Level
$0.0653
Bollinger Bands (100)
Sell
Level
0.0019 - 0.0219
Chaikin Money Flow
Buy
Level
499.7K
20-day SMA
Sell
Level
$0.0116
Relative Strength Index (RSI14)
Sell
Level
41.7432
ADX Line
Sell
Level
22.4713
Williams %R
Neutral
Level
-75.3769
50-day SMA
Sell
Level
$0.0118
MACD (12, 26)
Buy
Level
0.0025
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Sell
Level
-2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-28.3685)
Sell
CA Score
(Annual)
Level (-13.0106)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (16.3459)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. It offers T2Dx instrument, T2Bacteria, T2Candida, T2Biothreat panels, and T2MR technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.
Stock Forecast FAQ
In the current month, TTOO has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The TTOO average analyst price target in the past 3 months is $3.0000.
-
Where Will T2 Biosystems, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that T2 Biosystems, Inc. share price will rise to $3.0000 per share over the next 12 months.
-
What Do Analysts Say About T2 Biosystems, Inc.?
Analysts are divided on their view about T2 Biosystems, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that T2 Biosystems, Inc. is a Sell and believe this share price will drop from its current level to $3.0000.
-
What Is T2 Biosystems, Inc.'s Price Target?
The price target for T2 Biosystems, Inc. over the next 1-year time period is forecast to be $3.0000 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is TTOO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for T2 Biosystems, Inc. is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of TTOO?
You can purchase shares of T2 Biosystems, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase T2 Biosystems, Inc. shares.
-
What Is The T2 Biosystems, Inc. Share Price Today?
T2 Biosystems, Inc. was last trading at $0.0100 per share. This represents the most recent stock quote for T2 Biosystems, Inc.. Yesterday, T2 Biosystems, Inc. closed at $0.0050 per share.
-
How To Buy T2 Biosystems, Inc. Stock Online?
In order to purchase T2 Biosystems, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TTOO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TTOO
Sector
P/E ratio
--
23.88x
PEG ratio
--
-0.01x
P/B ratio
--
1.82x
Price / LTM sales
0.01x
1.59x
Growth Metrics
TTOO
Sector
Revenue growth
34.85%
4.73%
Earnings growth
--
11.11%
Revenue (5-year growth)
-7.29%
6.46%
Earnings forecast
-$0.97
-$0.18
Profitability
TTOO
Sector
Profitability FY 2023
-$8.2M
$3.6M
Return on invested capital
-478.19%
-31.77%
Return on assets
-150.57%
-28.18%
Return on equity
--
-37.47%
Earnings Date
Last Earnings Date
Jun
11
Next Earnings Date
Jan
3
Estimated Next Earnings Date
Apr
4
Balance Sheet
TTOO
Sector
Total cash
$2.1M
$26.3M
Short term investments
--
$26M
Total assets
$34.8M
$76.9M
Long term debt
$11.9M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
45
CTEV alert for Jan 2
Claritev Corp. [CTEV] is down 20.7% over the past day.
Sell
47
ASTS alert for Jan 2
AST Spacemobile, Inc. [ASTS] is up 14.94% over the past day.
Sell
45
BIDU alert for Jan 2
Baidu, Inc. [BIDU] is up 15.01% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
